{"id":"tavo","_chembl":{"chemblId":"CHEMBL4298206","moleculeType":"Gene"},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Tavo","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T06:47:02.927765+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T06:47:09.547164+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tavo","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T06:47:10.460610+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4298206/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T06:47:11.096439+00:00"}},"_dailymed":{"setId":"ada4a381-644f-8c5e-e053-2995a90a7cf3","title":"TAVOS HAND SANITIZER GEL (ISOPROPYL ALCOHOL) GEL [TAVOS INDUSTRIES INC.]"},"_scrapedAt":"2026-03-28T03:49:24.618Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T06:47:13.189676+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT04526730","phase":"PHASE2","title":"Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2020-12-22","conditions":"Melanoma","enrollment":17},{"nctId":"NCT04627675","phase":"PHASE1","title":"CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2)","status":"TERMINATED","sponsor":"Providence Health & Services","startDate":"2020-12-30","conditions":"SARS-CoV-2","enrollment":16},{"nctId":"NCT03567720","phase":"PHASE2","title":"Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC","status":"UNKNOWN","sponsor":"OncoSec Medical Incorporated","startDate":"2018-10-11","conditions":"Triple Negative Breast Cancer","enrollment":65},{"nctId":"NCT01502293","phase":"PHASE2","title":"Trial of pIL-12 Electroporation Malignant Melanoma","status":"COMPLETED","sponsor":"OncoSec Medical Incorporated","startDate":"2012-02-14","conditions":"Melanoma","enrollment":51},{"nctId":"NCT01440816","phase":"PHASE2","title":"IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer","status":"COMPLETED","sponsor":"OncoSec Medical Incorporated","startDate":"2012-01-03","conditions":"Merkel Cell Carcinoma","enrollment":15},{"nctId":"NCT01579318","phase":"PHASE2","title":"Phase II Intratumoral IL12 Plasmid Electroporation in Cutaneous Lymphoma","status":"TERMINATED","sponsor":"OncoSec Medical Incorporated","startDate":"2012-06-08","conditions":"Cutaneous T Cell Lymphomas (CTCL), Mycosis Fungoides (MF)","enrollment":2},{"nctId":"NCT02345330","phase":"PHASE2","title":"Trial of pIL-12 Electroporation in Squamous Cell Carcinoma of the Head and Neck (IL12HNSCC)","status":"TERMINATED","sponsor":"OncoSec Medical Incorporated","startDate":"2015-05-21","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":4},{"nctId":"NCT03823131","phase":"PHASE2","title":"Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat","status":"TERMINATED","sponsor":"Chase Heaton, MD","startDate":"2019-05-02","conditions":"Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Unresectable Head and Neck Squamous Cell Carcinoma","enrollment":14},{"nctId":"NCT03132675","phase":"PHASE2","title":"Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Either Pembrolizumab or Nivolumab Treatment","status":"UNKNOWN","sponsor":"OncoSec Medical Incorporated","startDate":"2017-10-03","conditions":"Stage III/IV Melanoma","enrollment":143}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL4298206"},"_approvalHistory":[],"publicationCount":23,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Tavo","genericName":"Tavo","companyName":"H. Lee Moffitt Cancer Center and Research Institute","companyId":"h-lee-moffitt-cancer-center-and-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T06:47:13.189676+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}